CO5180585A1 - Formulaciones en granulos de quetiapina, su preparacion y su uso - Google Patents

Formulaciones en granulos de quetiapina, su preparacion y su uso

Info

Publication number
CO5180585A1
CO5180585A1 CO00070974A CO00070974A CO5180585A1 CO 5180585 A1 CO5180585 A1 CO 5180585A1 CO 00070974 A CO00070974 A CO 00070974A CO 00070974 A CO00070974 A CO 00070974A CO 5180585 A1 CO5180585 A1 CO 5180585A1
Authority
CO
Colombia
Prior art keywords
granules
bed
formulations
preparation
formulation
Prior art date
Application number
CO00070974A
Other languages
English (en)
Spanish (es)
Inventor
Brown Daniel Boyd
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5180585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5180585A1 publication Critical patent/CO5180585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CO00070974A 1999-09-21 2000-09-19 Formulaciones en granulos de quetiapina, su preparacion y su uso CO5180585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation

Publications (1)

Publication Number Publication Date
CO5180585A1 true CO5180585A1 (es) 2002-07-30

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00070974A CO5180585A1 (es) 1999-09-21 2000-09-19 Formulaciones en granulos de quetiapina, su preparacion y su uso

Country Status (37)

Country Link
US (3) US6599897B1 (https=)
EP (1) EP1218009B1 (https=)
JP (1) JP2003509461A (https=)
KR (1) KR100748823B1 (https=)
CN (3) CN1899288A (https=)
AR (1) AR032596A1 (https=)
AT (1) ATE288272T1 (https=)
AU (1) AU776292B2 (https=)
BG (1) BG65469B1 (https=)
BR (1) BR0014107A (https=)
CA (1) CA2383131A1 (https=)
CO (1) CO5180585A1 (https=)
CZ (1) CZ301585B6 (https=)
DE (1) DE60017923T2 (https=)
DK (1) DK1218009T3 (https=)
EE (1) EE200200150A (https=)
EG (1) EG24226A (https=)
ES (1) ES2235941T3 (https=)
GB (2) GB9922271D0 (https=)
HK (1) HK1047706B (https=)
HU (1) HUP0203531A3 (https=)
IL (2) IL148440A0 (https=)
IS (1) IS2139B (https=)
MX (1) MXPA02002627A (https=)
MY (1) MY130208A (https=)
NO (1) NO320908B1 (https=)
NZ (1) NZ517549A (https=)
PL (1) PL198824B1 (https=)
PT (1) PT1218009E (https=)
RU (1) RU2256453C2 (https=)
SI (1) SI1218009T1 (https=)
SK (1) SK286884B6 (https=)
TR (1) TR200200716T2 (https=)
TW (1) TWI226832B (https=)
UA (1) UA73529C2 (https=)
WO (1) WO2001021179A1 (https=)
ZA (1) ZA200201709B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US8048876B2 (en) 2005-04-21 2011-11-01 Medichem S.A. Process for preparing quetiapine and quetiapine fumarate
US20100178333A1 (en) 2006-01-25 2010-07-15 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
EP2063876A1 (en) * 2006-07-28 2009-06-03 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
US20080085888A1 (en) * 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
WO2008052354A1 (en) * 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
DE602007009036D1 (de) 2007-02-14 2010-10-21 Lesvi Laboratorios Sl Pharmazeutische Zusammensetzungen mit Quetiapinfumarat
CN102014655B (zh) * 2008-02-27 2016-01-13 洲际大品牌有限责任公司 多区糖食
EP2262486B1 (en) 2008-08-01 2013-01-02 KRKA, Tovarna Zdravil, D.D., Novo Mesto Quetiapine composition
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
EP4142735A4 (en) * 2020-04-29 2024-06-19 Stepan Company SOLID COMPOSITIONS CONTAINING AMINE, PROTONATED AMINE OR QUATERNARY AMMONIUM COMPOUNDS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
EP0416773B1 (en) * 1989-08-31 1993-03-03 Takeda Chemical Industries, Ltd. Vitamin b12 composition
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
KR100313649B1 (ko) * 1992-11-09 2002-02-28 더 부츠 캄파니 피엘씨 신경계질환치료제로서유용한1,4-벤조티아제핀,이의제조방법및이를포함하는약제학적조성물
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
ES2235941T3 (es) 2005-07-16
BG65469B1 (bg) 2008-09-30
EE200200150A (et) 2003-04-15
PL357369A1 (en) 2004-07-26
IS6308A (is) 2002-03-19
NZ517549A (en) 2003-10-31
NO20021394L (no) 2002-03-20
ATE288272T1 (de) 2005-02-15
CZ301585B6 (cs) 2010-04-21
NO20021394D0 (no) 2002-03-20
IL148440A0 (en) 2002-09-12
TR200200716T2 (tr) 2002-06-21
SI1218009T1 (en) 2005-06-30
PL198824B1 (pl) 2008-07-31
PT1218009E (pt) 2005-05-31
GB0021406D0 (en) 2000-10-18
CN1331472C (zh) 2007-08-15
AU776292B2 (en) 2004-09-02
CN1188130C (zh) 2005-02-09
WO2001021179A1 (en) 2001-03-29
KR20020033186A (ko) 2002-05-04
UA73529C2 (uk) 2005-08-15
CN1626094A (zh) 2005-06-15
BR0014107A (pt) 2002-08-20
MY130208A (en) 2007-06-29
HUP0203531A2 (hu) 2003-02-28
DK1218009T3 (da) 2005-05-09
EG24226A (en) 2008-11-10
BG106509A (en) 2002-12-29
NO320908B1 (no) 2006-02-13
AR032596A1 (es) 2003-11-19
KR100748823B1 (ko) 2007-08-13
CA2383131A1 (en) 2001-03-29
US6599897B1 (en) 2003-07-29
HK1047706B (en) 2005-06-10
GB9922271D0 (en) 1999-11-17
IL148440A (en) 2007-07-04
US20040228914A1 (en) 2004-11-18
DE60017923T2 (de) 2006-01-12
DE60017923D1 (de) 2005-03-10
ZA200201709B (en) 2003-05-28
AU7302300A (en) 2001-04-24
HK1047706A1 (en) 2003-03-07
JP2003509461A (ja) 2003-03-11
EP1218009B1 (en) 2005-02-02
EP1218009A1 (en) 2002-07-03
US20060159768A1 (en) 2006-07-20
IS2139B (is) 2006-08-15
SK3722002A3 (en) 2002-07-02
TWI226832B (en) 2005-01-21
CN1899288A (zh) 2007-01-24
US7022692B2 (en) 2006-04-04
HUP0203531A3 (en) 2004-12-28
MXPA02002627A (es) 2002-07-30
RU2256453C2 (ru) 2005-07-20
SK286884B6 (sk) 2009-07-06
CZ2002974A3 (cs) 2002-06-12
CN1374867A (zh) 2002-10-16

Similar Documents

Publication Publication Date Title
CO5180585A1 (es) Formulaciones en granulos de quetiapina, su preparacion y su uso
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
SV1997000049A (es) Conjugados de interferones ref. 12614 sv
CO5200832A1 (es) Derivados de acidos heterociclicos, o una sal farmaceuticamente aceptable de los mismos, que son agentes antidiabeticos y antiobesidad
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
DE60037395D1 (de) Herstellung eines halbleiter-bauelementes
ES2182079T3 (es) Composiciones farmaceuticas de liberacion sostenida que contienen un derivado de dibenzotiazepina.
EP1229820A4 (en) CLOSURE OF TUBULAR, ANATOMICAL STRUCTURES THROUGH ENERGY INPUT
AR042937A2 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
FR11C0041I2 (fr) Formulations de solutions pharmaceutiques stables pour inhalateurs a dosage mesure pressurises
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
ES2571703T3 (es) Formulaciones de oxicodona de una vez al día
BR9611263A (pt) Pastilha de limpesa para vaso sanitário.
CL2008000134A1 (es) Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
AR013282A1 (es) Articulo absorbente desechable formado anatomicamente con alta resiliencia del lobulo
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
FR2808663B1 (fr) Piece d'appui d'un sac a porter
AU2001295452A1 (en) Use of ectoine or ectoine derivatives for oral care
ITMI20000380A0 (it) Uso di composti fluorurati per conferire proprieta' release
IT1313383B1 (it) Struttura efficiente di integratore a capacita' commutate integrato
HUP0302344A3 (en) A process for the preparation of alpha-n-acyl alpha' chloroketones
AU2001260417A1 (en) Use of a cell extract of at least a plant of the family pontederiaceae as anti-pollution agent
IT9020943A0 (it) Composizione farmaceutica per uso orale a rilascio modificato di antiinfiammatori non steroidei
PE20011255A1 (es) FORMULACIONES ESTABILIZADAS DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO Y SUS SALES

Legal Events

Date Code Title Description
FC Application refused